BioSpace News Archive

Hyperion Metals Limited (ASX: HYM) (“Hyperion” or “the Company”) is pleased to announce the strengthening of the Company’s Scientific and Technical Advisory Board (“Advisory Board”) through the addition of Dr. Kesh Keshavan.

Vitro Biopharma recorded quarter ended January 31st, 2021 revenues of $ 127,492 vs $225,921 a decrease of 44% over the prior comparative quarter directly attributed to the COVID-19 pandemic.

Eurofins Viracor, one of the largest and most recognized infectious diseases testing laboratories in the United States, and Transplant Genomics, the trusted global partner in precision biomarkers for the transplant community innovating to improve patient outcomes, announce that the New York State Department of Health Clinical Laboratory Evaluation Program

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, today announced that the following poster, highlighting a preclinical research collaboration using its ARCUS® genome editing platform for treatment of transthyretin amyloidosis (ATTR), will be presented at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting,

Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced three data presentations to be delivered at the upcoming American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting, being held virtually May 11-14, 2021.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the company’s New Drug Application (NDA) for mobocertinib (TAK-788)

REGENXBIO Inc. (Nasdaq: RGNX) today announced that four oral and nine poster presentations will be presented at the American Society of Gene and Cell Therapy’s 24th Annual Meeting taking place from May 11 to 14, 2021, in virtual format.

AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in China and the United States, announced that it plans to report its fiscal year 2020 unaudited financial results ended December 31, 2020, before the open of U.S. markets on Friday, April 30, 2021.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced that the Company expects to report business results for the first quarter of 2021 after the market closes on Wednesday, May 5, 2021.

Marker Therapeutics, Inc. (Nasdaq:MRKR), today announced that it will present data detailing a new robotics technology to aid in multi-tumor-associated antigen (mTAA)-specific T cell therapy manufacturing at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting,